HBOT for Sudden Sensorineural Hearing Loss (SSNHL)

UHMS-approved as adjunct to corticosteroids for idiopathic SSNHL. Best outcomes when started within 2 weeks of onset. CMS covered since 2021.

HBOT Hub — http://localhost:3003/conditions/sudden-hearing-loss · Printed October 11, 2026 · UHMS approved · ENT · Time-sensitive

GRADE Evidence Rating

Bennett 2012 Cochrane shows PTA improvement when HBOT delivered within 2 weeks. UHMS added 2019.

Overview

HBOT is UHMS-approved for idiopathic sudden sensorineural hearing loss when initiated within 2 weeks of onset. Combination with corticosteroids yields the best outcomes. The mechanism involves overcoming cochlear hypoxia. Added to CMS coverage in 2021.

How HBOT Works

The inner ear has high metabolic demand and limited collateral circulation, making it vulnerable to ischaemic injury. ISSNHL is hypothesised to involve cochlear microvascular compromise. HBOT elevates plasma oxygen delivery to cochlear structures, supporting hair cell survival during the critical early window. Combined with corticosteroid anti-inflammatory effects, HBOT appears to improve the proportion of patients who recover functional hearing.

Clinical Protocol

Standard ISSNHL HBOT: 2.0–2.4 ATA sessions, 10–20 total, 5 days per week. Initiated as soon as possible after diagnosis. Combined with oral prednisone or intratympanic steroid injection per otolaryngology protocol.

Cautions & Considerations

Typical protocol	10–20 sessions at 2.0–2.4 ATA, 90 minutes each
Evidence level	Moderate — UHMS approved
FDA / regulatory status	FDA-approved indication

Time-critical — must initiate within 14 days (CMS) and ideally within days of onset.
Adjunct to — not replacement for — corticosteroid therapy.
Requires otolaryngology referral and audiometry.
Standard HBOT contraindications apply.

Key Research

Indexed studies

Questions to Ask Your Doctor

Am I a candidate for HBOT for this condition given my medical history and current treatments?
What pressure (ATA) and session count would you recommend, and why?
Is treatment at this centre UHMS-accredited? What is the chamber type (monoplace or multiplace)?
What is the expected response rate and typical timeline for improvement?
What are the specific contraindications and side-effect risks in my case?
What is the expected cost and insurance coverage status?
What alternative or complementary treatments should I consider?
How will we measure whether treatment is working?